{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:10:13Z","timestamp":1790838613962,"version":"4.1.0"},"reference-count":74,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2020,9,29]]},"published-print":{"date-parts":[[2020,10]]},"abstract":"\n Objective<\/jats:title>\n Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). We report the largest integrated safety analysis of tofacitinib, as of March 2017, using data from phase I, II, III, IIIb\/IV and long-term extension studies in adult patients with RA.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Data were pooled for patients with RA who received \u22651 tofacitinib dose. Incidence rates (IRs; patients with events\/100 patient-years [PY]; 95% CIs) of first-time occurrences were obtained for adverse events (AEs) of interest.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n 7061 patients received tofacitinib (total exposure: 22\u00a0875 PY; median [range] exposure: 3.1 [0 to 9.6] years). IRs (95% CI) for serious AEs, serious infections, herpes zoster (all), opportunistic infections (excluding tuberculosis [TB]) and TB were 9.0 (8.6 to 9.4), 2.5 (2.3 to 2.7), 3.6 (3.4 to 3.9), 0.4 (0.3 to 0.5) and 0.2 (0.1 to 0.2), respectively. IRs (95% CI) for malignancies (excluding non-melanoma skin cancer [NMSC]), NMSC and lymphomas were 0.8 (0.7 to 0.9), 0.6 (0.5 to 0.7) and 0.1 (0.0 to 0.1), respectively. IRs (95% CI) for gastrointestinal perforations, deep vein thrombosis, pulmonary embolism, venous thromboembolism, arterial thromboembolism and major adverse cardiovascular events were 0.1 (0.1 to 0.2), 0.2 (0.1 to 0.2), 0.1 (0.1 to 0.2), 0.3 (0.2 to 0.3), 0.4 (0.3 to 0.5) and 0.4 (0.3 to 0.5), respectively. IR (95% CI) for mortality was 0.3 (0.2 to 0.3). IRs generally remained consistent across 6-month intervals to >78\u00a0months.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n This represents the largest clinical dataset for a JAK inhibitor in RA to date. IRs remained consistent with previous reports from the tofacitinib RA clinical development programme, and stable over time.<\/jats:p>\n <\/jats:sec>\n \n Trial registration numbers<\/jats:title>\n \n NCT01262118;\n NCT01484561<\/jats:ext-link>\n ;\n NCT00147498<\/jats:ext-link>\n ;\n NCT00413660<\/jats:ext-link>\n ;\n NCT00550446<\/jats:ext-link>\n ;\n NCT00603512<\/jats:ext-link>\n ;\n NCT00687193<\/jats:ext-link>\n ;\n NCT01164579<\/jats:ext-link>\n ;\n NCT00976599<\/jats:ext-link>\n ;\n NCT01059864<\/jats:ext-link>\n ;\n NCT01359150<\/jats:ext-link>\n ;\n NCT02147587<\/jats:ext-link>\n ;\n NCT00960440<\/jats:ext-link>\n ;\n NCT00847613<\/jats:ext-link>\n ;\n NCT00814307<\/jats:ext-link>\n ;\n NCT00856544<\/jats:ext-link>\n ;\n NCT00853385<\/jats:ext-link>\n ;\n NCT01039688<\/jats:ext-link>\n ;\n NCT02187055<\/jats:ext-link>\n ;\n NCT00413699<\/jats:ext-link>\n ;\n NCT00661661<\/jats:ext-link>\n .\n <\/jats:p>\n For summary of phase I, phase II, phase III, phase IIIb\/IV and LTE studies included in the integrated safety analysis, see online supplemental table 1.<\/jats:p>\n <\/jats:sec>","DOI":"10.1136\/rmdopen-2020-001395","type":"journal-article","created":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T15:50:10Z","timestamp":1604073010000},"page":"e001395","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":176,"title":["Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme"],"prefix":"10.1136","volume":"6","clinical-trial-number":[{"clinical-trial-number":"nct01484561","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00147498","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00413660","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00550446","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00603512","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00687193","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01164579","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00976599","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01059864","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01359150","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02147587","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00960440","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00847613","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00814307","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00856544","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00853385","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01039688","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02187055","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00413699","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00661661","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02092467","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00413699","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00413699","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Stanley B","family":"Cohen","sequence":"first","affiliation":[{"name":"Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"University of Occupational and Environmental Health, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4244-5417","authenticated-orcid":false,"given":"Xavier","family":"Mariette","sequence":"additional","affiliation":[{"name":"Paris-Saclay University, AP-HP, INSERM, Le Kremlin Bic\u00eatre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8907-8976","authenticated-orcid":false,"given":"Jeffrey R","family":"Curtis","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0703-1208","authenticated-orcid":false,"given":"Eun Bong","family":"Lee","sequence":"additional","affiliation":[{"name":"Seoul National University, Seoul, Korea (the Democratic People\u2019s Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2571-788X","authenticated-orcid":false,"given":"Peter","family":"Nash","sequence":"additional","affiliation":[{"name":"Department of Medicine, Griffith University, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3892-6947","authenticated-orcid":false,"given":"Kevin L","family":"Winthrop","sequence":"additional","affiliation":[{"name":"Oregon Health and Science University, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Charles-Schoeman","sequence":"additional","affiliation":[{"name":"University of California, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1096-0868","authenticated-orcid":false,"given":"Lisy","family":"Wang","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Groton, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie","family":"Chen","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Kwok","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinaki","family":"Biswas","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Peapack, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Madsen","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Wollenhaupt","sequence":"additional","affiliation":[{"name":"Struenseehaus Centre for Rheumatology and Clinical Immunology, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,10,30]]},"reference":[{"key":"2025090312323939000_6.3.e001395.1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204627"},{"key":"2025090312323939000_6.3.e001395.2","first-page":"1","article-title":"American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"2016","author":"Singh","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025090312323939000_6.3.e001395.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210715"},{"key":"2025090312323939000_6.3.e001395.4","doi-asserted-by":"publisher","DOI":"10.1002\/art.33383"},{"key":"2025090312323939000_6.3.e001395.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.24567"},{"key":"2025090312323939000_6.3.e001395.6","doi-asserted-by":"publisher","DOI":"10.1002\/art.33419"},{"key":"2025090312323939000_6.3.e001395.7","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/acr.20494","article-title":"Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"63","author":"Tanaka","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312323939000_6.3.e001395.8","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2014.995875"},{"key":"2025090312323939000_6.3.e001395.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61424-X"},{"key":"2025090312323939000_6.3.e001395.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109071"},{"key":"2025090312323939000_6.3.e001395.11","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-159-4-201308200-00006"},{"key":"2025090312323939000_6.3.e001395.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310476"},{"key":"2025090312323939000_6.3.e001395.13","doi-asserted-by":"publisher","DOI":"10.1002\/art.37816"},{"key":"2025090312323939000_6.3.e001395.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112072"},{"key":"2025090312323939000_6.3.e001395.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31618-5"},{"key":"2025090312323939000_6.3.e001395.16","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13075-016-0932-2","article-title":"Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study","volume":"18","author":"Yamanaka","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2025090312323939000_6.3.e001395.17","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1866-2"},{"key":"2025090312323939000_6.3.e001395.18","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130683"},{"key":"2025090312323939000_6.3.e001395.19","unstructured":"US Food and Drug Administration. XELJANZ (tofacitinib): highlights of prescribing information. 2019. Available http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=959 (accessed 2 Mar 2020)"},{"key":"2025090312323939000_6.3.e001395.20","unstructured":"US Food and Drug Administration. Safety trial finds risk of blood clots in the lungs and death with higher dose of tofacitinib (Xeljanz, Xeljanz XR) in rheumatoid arthritis patients; FDA to investigate. 2019. Available https:\/\/www.fda.gov\/media\/120485\/download (accessed 11 Mar 2020)"},{"key":"2025090312323939000_6.3.e001395.21","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.51"},{"key":"2025090312323939000_6.3.e001395.22","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-018-0651-5"},{"key":"2025090312323939000_6.3.e001395.23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210457"},{"key":"2025090312323939000_6.3.e001395.24","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302"},{"key":"2025090312323939000_6.3.e001395.25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205847"},{"key":"2025090312323939000_6.3.e001395.26","unstructured":"Wollenhaupt J , Silverfield J , Lee EB , et al. Tofacitinib, an oral Janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension studies over 8 years [abstract]. Arthritis Rheumatol 2016;68(Suppl 10):1647."},{"key":"2025090312323939000_6.3.e001395.27","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171361"},{"key":"2025090312323939000_6.3.e001395.28","doi-asserted-by":"crossref","unstructured":"Strand V , Ahadieh S , DeMasi R , et al. THU0211 Meta-analysis of serious infections with baricitinib, tofacitinib and biologic DMARDs in rheumatoid arthritis [abstract]. Ann Rheum Dis 2017;76(Suppl 2):THU0211. Available https:\/\/ard.bmj.com\/content\/76\/Suppl_2\/284.1","DOI":"10.1136\/annrheumdis-2017-eular.2439"},{"key":"2025090312323939000_6.3.e001395.29","unstructured":"Cohen S , van Vollenhoven R , Winthrop K , et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase 3 clinical program [abstract]. Arthritis Rheumatol 2019;71(Suppl 10):509. Available https:\/\/acrabstracts.org\/abstract\/safety-profile-of-upadacitinib-in-rheumatoid-arthritis-integrated-analysis-from-the-select-phase-3-clinical-program\/"},{"key":"2025090312323939000_6.3.e001395.30","doi-asserted-by":"crossref","unstructured":"Genovese MC , Smolen JS , Takeuchi T , et al. FRI0123 Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 8.4 years: an updated integrated safety analysis [abstract]. Ann Rheum Dis 2020;79(Suppl 1):FRI0123. Available https:\/\/ard.bmj.com\/content\/79\/Suppl_1\/642.1","DOI":"10.1136\/annrheumdis-2020-eular.1723"},{"key":"2025090312323939000_6.3.e001395.31","doi-asserted-by":"crossref","unstructured":"Cohen SB , Van Vollenhoven R , Curtis JR , et al. THU0197 Safety profile of upadacitinib up to 3 years of exposure in patients with rheumatoid arthritis [abstract]. Ann Rheum Dis 2020;79(Suppl 1):THU0197. Available https:\/\/ard.bmj.com\/content\/79\/Suppl_1\/319.info","DOI":"10.1136\/annrheumdis-2020-eular.2396"},{"key":"2025090312323939000_6.3.e001395.32","unstructured":"US Food and Drug Administration. RINVOQ (upadacitinib): highlights of prescribing information. 2019. Available https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/211675s000lbl.pdf (accessed 27 Apr 2020)"},{"key":"2025090312323939000_6.3.e001395.33","unstructured":"European Medicines Agency. Xeljanz (tofacitinib citrate) - summary of product characteristics, 2020. Available https:\/\/www.medicines.org.uk\/emc\/medicine\/33167 (accessed 7 Feb 2020)"},{"key":"2025090312323939000_6.3.e001395.34","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/art.40780","article-title":"Evaluation of the short-, mid-, and long-term effects of tofacitinib on lymphocytes in patients with rheumatoid arthritis","volume":"71","author":"van Vollenhoven","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025090312323939000_6.3.e001395.35","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/art.38745","article-title":"Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis","volume":"66","author":"Winthrop","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2025090312323939000_6.3.e001395.36","unstructured":"Winthrop KL , Valdez H , Mortensen E , et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2013;65(Suppl):2490. Available https:\/\/acrabstracts.org\/abstract\/herpes-zoster-and-tofacitinib-therapy-in-patients-with-rheumatoid-arthritis\/"},{"key":"2025090312323939000_6.3.e001395.37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507247"},{"key":"2025090312323939000_6.3.e001395.38","unstructured":"Winthrop KL , Lindsey S , Weinblatt M , et al. Herpes zoster in patients with moderate to severe rheumatoid arthritis treated with baricitinib [abstract]. Arthritis Rheumatol 2016;68(Suppl 10):3027. Available https:\/\/acrabstracts.org\/abstract\/herpes-zoster-in-patients-with-moderate-to-severe-rheumatoid-arthritis-treated-with-baricitinib\/"},{"key":"2025090312323939000_6.3.e001395.39","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/art.40189","article-title":"Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy","volume":"69","author":"Winthrop","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025090312323939000_6.3.e001395.40","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/acr.23769","article-title":"Risk for herpes zoster in tofacitinib-treated rheumatoid arthritis patients with and without concomitant methotrexate and glucocorticoids","volume":"71","author":"Curtis","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312323939000_6.3.e001395.41","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204960"},{"key":"2025090312323939000_6.3.e001395.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2010.12.004"},{"key":"2025090312323939000_6.3.e001395.43","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu104"},{"key":"2025090312323939000_6.3.e001395.44","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207319"},{"key":"2025090312323939000_6.3.e001395.45","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120906"},{"key":"2025090312323939000_6.3.e001395.46","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120964"},{"key":"2025090312323939000_6.3.e001395.47","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203660"},{"key":"2025090312323939000_6.3.e001395.48","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160420"},{"key":"2025090312323939000_6.3.e001395.49","doi-asserted-by":"crossref","DOI":"10.1186\/ar3455","article-title":"Integrated safety in tocilizumab clinical trials","volume":"13","author":"Schiff","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"2025090312323939000_6.3.e001395.50","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/art.38687","article-title":"Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment","volume":"66","author":"Alten","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2025090312323939000_6.3.e001395.51","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.043166"},{"key":"2025090312323939000_6.3.e001395.52","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-eular.2281"},{"key":"2025090312323939000_6.3.e001395.53","unstructured":"Citera G , Mysler E , Madariaga H , et al. Low interstitial lung disease event rate in patients with rheumatoid arthritis: pooled post hoc analysis of data from the tofacitinib clinical development program [abstract]. Arthritis Rheumatol 2018;70(Suppl 10):525. Available https:\/\/acrabstracts.org\/abstract\/low-interstitial-lung-disease-event-rate-in-patients-with-rheumatoid-arthritis-pooled-post-hoc-analysis-of-data-from-the-tofacitinib-clinical-development-program\/"},{"key":"2025090312323939000_6.3.e001395.54","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0728-9"},{"key":"2025090312323939000_6.3.e001395.55","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/acr.23421","article-title":"Lymphoma in the tofacitinib rheumatoid arthritis clinical development program","volume":"70","author":"Mariette","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312323939000_6.3.e001395.56","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201244"},{"key":"2025090312323939000_6.3.e001395.57","doi-asserted-by":"publisher","DOI":"10.1002\/art.22864"},{"key":"2025090312323939000_6.3.e001395.58","doi-asserted-by":"crossref","unstructured":"Gomez-Reino JJ , Checchio T , Geier J , et al. THU0196 Systematic review and meta-analysis of malignancies, excluding non-melanoma skin cancer, in patients with rheumatoid arthritis treated with tofacitinib or biologic disease-modifying antirheumatic drugs [abstract]. Ann Rheum Dis 2017;76(Suppl 2):THU0196. Available https:\/\/ard.bmj.com\/content\/76\/Suppl_2\/277.1","DOI":"10.1136\/annrheumdis-2017-eular.1960"},{"key":"2025090312323939000_6.3.e001395.59","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000213","article-title":"Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab","volume":"2","author":"Rubbert-Roth","year":"2016","journal-title":"RMD Open"},{"key":"2025090312323939000_6.3.e001395.60","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-000942","article-title":"Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn\u2019s disease: a pooled analysis of 11 317 patients across clinical trials","volume":"5","author":"Curtis","year":"2019","journal-title":"RMD Open"},{"key":"2025090312323939000_6.3.e001395.61","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1002\/acr.21764","article-title":"Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis","volume":"64","author":"Curtis","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312323939000_6.3.e001395.62","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-016-0037-z"},{"key":"2025090312323939000_6.3.e001395.63","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx145"},{"key":"2025090312323939000_6.3.e001395.64","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/acr.22039","article-title":"Risk of venous thromboembolism in patients with rheumatoid arthritis","volume":"65","author":"Kim","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312323939000_6.3.e001395.65","unstructured":"Mease PJ , Kremer J , Cohen S , et al. Incidence of thromboembolic events in the tofacitinib rheumatoid arthritis, psoriasis, psoriatic arthritis and ulcerative colitis development programs [abstract]. Arthritis Rheumatol 2017;69(Suppl 10):16L. Available https:\/\/acrabstracts.org\/abstract\/incidence-of-thromboembolic-events-in-the-tofacitinib-rheumatoid-arthritis-psoriasis-psoriatic-arthritis-and-ulcerative-colitis-development-programs\/"},{"key":"2025090312323939000_6.3.e001395.66","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/art.38920","article-title":"An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy","volume":"67","author":"Rao","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025090312323939000_6.3.e001395.67","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/art.40841","article-title":"Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis","volume":"71","author":"Taylor","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025090312323939000_6.3.e001395.68","unstructured":"Curtis JR , Schulze-Koops H , Takiya L , et al. Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis. Clin Exp Rheumatol 2017;35:390\u2013400. Available https:\/\/pubmed.ncbi.nlm.nih.gov\/28079500\/"},{"key":"2025090312323939000_6.3.e001395.69","doi-asserted-by":"crossref","unstructured":"Winthrop K , Gold D , Henrohn D , et al. SAT0139 age-based (<65 vs \u226565 years) incidence of infections and serious infections in tofacitinib-, adalimumab- and placebo-treated patients with rheumatoid arthritis: a post hoc analysis of phase 2, phase 3 and phase 3b\/4 tofacitinib studies [abstract]. Ann Rheum Dis 2020;79(Suppl 1):SAT0139. Available https:\/\/ard.bmj.com\/content\/79\/Suppl_1\/1007.info","DOI":"10.1136\/annrheumdis-2020-eular.1432"},{"key":"2025090312323939000_6.3.e001395.70","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000262","article-title":"Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis","volume":"2","author":"Fleischmann","year":"2016","journal-title":"RMD Open"},{"key":"2025090312323939000_6.3.e001395.71","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2019-eular.587","article-title":"THU0193 efficacy of tofacitinib monotherapy, tofacitinib with methotrexate and adalimumab with methotrexate in patients with early (\u22642 years) vs established (>2 years) rheumatoid arthritis: a post hoc analysis of data from ORAL strategy [abstract]","volume":"78","author":"Takeuchi","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2025090312323939000_6.3.e001395.72","doi-asserted-by":"crossref","unstructured":"Fleischmann R , Wollenhaupt J , Cohen S , et al. SAT0247 Impact of glucocorticoids on efficacy and safety of tofacitinib with and without methotrexate and adalimumab with methotrexate for rheumatoid arthritis: results from a phase 3b\/4 randomised trial [abstract]. Ann Rheum Dis 2018;77(Suppl 2):SAT0247. Available https:\/\/ard.bmj.com\/content\/77\/Suppl_2\/985.2","DOI":"10.1136\/annrheumdis-2018-eular.1533"},{"key":"2025090312323939000_6.3.e001395.73","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2014.36"},{"key":"2025090312323939000_6.3.e001395.74","unstructured":"Kremer J , Cappelli LC , Etzel CJ , et al. Real-world data from a post-approval safety surveillance study of tofacitinib vs biologic DMARDS and conventional synthetic DMARDS: five-year results from a US-based rheumatoid arthritis registry [abstract]. Arthritis Rheumatol 2018;70(Suppl 10):1542. Available https:\/\/acrabstracts.org\/abstract\/real-world-data-from-a-post-approval-safety-surveillance-study-of-tofacitinib-vs-biologic-dmards-and-conventional-synthetic-dmards-five-year-results-from-a-us-based-rheumatoid-arthritis-registry\/"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2020-001395","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:32:53Z","timestamp":1756927973000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2020-001395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":74,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,10,30]]},"published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1136\/rmdopen-2020-001395"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2020-001395","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10]]}}}